Latest Content

The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.

The ustekinumab biosimilar DMB-3115 matched reference therapy in efficacy and safety for moderate to severe plaque psoriasis, according to a phase 3 trial.

COVID-19 vaccination during pregnancy lowers hospitalization and preterm birth risks, providing key guidance for maternal care strategies.

Our top breast cancer stories in 2025 covered FDA approvals, new and failed therapies, screening gaps, and policy factors shaping treatment access and outcomes.

Linvoseltamab shows promise as a first-line therapy for multiple myeloma, offering high response rates and a simplified treatment approach.

AHA 2025 highlights included new guidelines and targeted approaches advancing heart failure and cardiovascular care.

The patient was a rare case of a patient with dedifferentiated liposarcoma and a high tumor mutational burden.

Top articles in 2025 covered advancements in acute myeloid leukemia treatments, including allogeneic CAR T-cell therapy.

Eunice Wang, MD, highlights breakthroughs in menin inhibitors for acute leukemias, showcasing promising combination therapies and addressing treatment challenges at ASH 2025.